Biomea Fusion to report Phase I results for GLP-1 agonist BMF-650 on October 13

Biomea Fusion will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on October 13.

Detected & updated continuously · Source: Nebula